Non-invasive Prenatal Testing (NIPT) Market is Fueled by Trisomy During the Forecast Period
Growing
incidence of chromosomal abnormalities and availability of advanced screening
technologies is expected to drive the Global Non-invasive Prenatal Testing
(NIPT) Market growth in the forecast period, 2024-2028.
According
to TechSci Research report, “Non-invasive Prenatal Testing (NIPT) Market -
Industry Size, Share, Trends, Opportunity, and Forecast, 2018–2028F” Global
Non-invasive Prenatal Testing (NIPT) Market stood at USD4.03 billion in 2022
and is expected to grow at a CAGR of 7.38% through 2028. The increasing
prevalence of genetic disorders in fetuses is a significant driver for market
growth. Moreover, advancements in technology within the life sciences and
healthcare industries are providing a substantial boost to the market. For
example, the development of DNA sequencing technologies, breakthroughs in
molecular research, and regenerative medicines have opened up immense
possibilities for early detection and prevention of serious diseases.
Additionally, the growing acceptance rate of prenatal testing, coupled with
increased health consciousness and awareness among the general population, is
driving market growth. Healthcare providers and expecting parents are
increasingly turning to alternative diagnostics for genetic disorders such as
spina bifida, cleft palate, and sickle cell anemia, enabling early intervention
during fetal development. Furthermore, the trend of childbearing at a higher
maternal age (35 years or older) is also positively influencing market growth,
despite the associated health complications including high blood pressure,
reduced fertility, and increased risk of chromosomal anomalies in the fetus.
The
demand for Non-Invasive Prenatal Testing (NIPT) is rising in various countries
due to several factors. These include an increasing number of doctors opting
for advanced genetic testing for high-risk pregnancies, a desire to postpone
pregnancy, and a rise in pregnancy-related complications during the second or
third trimester. Traditional invasive prenatal testing methods like chorionic
villus sampling and amniocentesis can lead to complications such as
miscarriage. Consequently, there has been a decline in the utilization of these
procedures and a surge in demand for more efficient, noninvasive, and safe
tests. NIPT utilizes cell-free fetal DNA (cffDNA) present in the mother's blood
to detect common trisomies such as Turner syndrome, Down syndrome, fetal rhesus
D status, sex chromosome disorders, and determine fetal sex. The market for
NIPT is highly competitive, with numerous key players operating in the field.
To maintain a stronghold in the market, companies are forming strategic
partnerships and collaborations. For example, in June 2021, Illumina
collaborated with Next Generation Genomic to introduce VeriSeq NIPT Solution
v2, a CE-IVD, NGS-based NIPT test in Thailand. This collaboration aims to
enhance patient access to next-generation sequencing-based NIPT. The market is
driven by constant improvements and advancements in existing products. Notably,
in April 2020, Natera expanded the coverage of its product Panorama to cater to
all pregnant women regardless of age or conditions. The introduction of innovative
products is expected to have a positive impact on the market. Moreover,
increased reimbursement coverage for newly introduced products is anticipated
to further boost product adoption.
Browse
over XX market data Figures spread through XX Pages and an in-depth TOC on
"Global Non-invasive Prenatal Testing (NIPT) Market.”
The
age of a woman at the time of delivery is commonly referred to as her maternal
age. Advancing maternal age can result in various health complications,
including decreased fertility, hypertension, and an elevated risk of
miscarriage, stillbirths, and maternal mortality. Additionally, due to errors
in chromosomal division, maternal age can contribute to a higher incidence of
genetic abnormalities in newborns. Neonates may exhibit conditions such as
microcephaly, a shortened neck, upward slanted eyes, weak muscle tone, and
complications related to the heart, intestines, and respiration. These findings
suggest a global increase in maternal advanced age, which is likely to result
in more health challenges. Consequently, the rising maternal age, coupled with
the growing prevalence of chromosomal abnormalities, is anticipated to drive
the demand for non-invasive prenatal testing (NIPT). The increasing occurrence
of chromosomal abnormalities, along with expanded applications of NIPT, are key
drivers of organic revenue growth in the market. Moreover, advancements in
existing tests, encompassing enhanced functionality, improved chemistry, and
bioinformatics analysis, are projected to fuel market expansion. The
enhancement of payment policies for routine and low-risk pregnancies serves as
a primary catalyst for market growth.
Notably,
Natera announced in December 2020 that Aetna, the leading U.S. health insurer,
would provide coverage for its non-invasive prenatal testing (NIPT) for all
pregnancies. One of the primary factors propelling the market for non-invasive
prenatal testing (NIPT) is the increasing average maternal age, which has
raised concerns regarding fetal well-being. Down syndrome, characterized by the
presence of an additional chromosome 21 resulting from a cell division error,
can significantly impact a fetus's cognitive abilities and physical
development. NIPT screening tests are considered safe for both the mother and
the baby, carrying no risk of miscarriage, and exhibiting a detection rate of
over 99 percent for Down syndrome cases. According to the National Down
Syndrome Society and the Centers for Disease Control and Prevention,
approximately one in every 700 babies in the United States is born with Down
syndrome, with 80 percent of Down syndrome cases occurring in older mothers.
The heightened risk of Down syndrome among older women is driving the market
for non-invasive prenatal testing.
The
Global Non-invasive Prenatal Testing (NIPT) Market is segmented into product
type, test type, method, application, end user, regional distribution, and
company.
Based
on the application, the market is categorized into Trisomy, Microdeletions
Symptoms, and Others. Trisomy holds the largest share in the global NIPT
market, encompassing gender identification, diagnosis of monogenic disorders,
Klinefelter syndrome, and the Rhesus (Rh) blood type. Trisomy remains the
largest application segment in the NIPT market, projected to grow at the
highest CAGR during the forecast period. The significant share and rapid growth
of this segment can be attributed to factors such as maternal age and the
increasing prevalence of chromosomal disorders.
Based
on region, North America segment is expected to grow during the forecast
period. In 2022, North America held the largest market share, followed by
Europe. The high demand for genetic testing in North America, substantial
research and development expenditures, a higher preterm birth rate, a
well-established research framework, and increased complicated birth rates are
expected to drive the expansion of the North America non-invasive prenatal
testing market. Furthermore, the robust reimbursement system in North America
also supports the demand for non-invasive prenatal testing in the region.
Major companies operating in Global Non-invasive Prenatal
Testing (NIPT) Market are:
- YOURGENE HEALTH Plc
- Illumina, Inc.
- Natera, Inc.
- Hoffman La Roche Ltd.
- Perkin Elmer Inc.
- Laboratory Corporation of America
Holdings
- Eurofins LifeCodex GmbH
- Progenity, Inc.
- Genesis Genetics
- Quest Diagnostics Incorporated
Download Free Sample Report
Customers can also request for 10% free customization on
this report.
“NIPT
has the potential to be incorporated into routine antenatal care, as indicated
by numerous healthcare specialists. Non-invasive prenatal testing is gaining
popularity among pregnant women as a safer alternative to amniocentesis,
especially as awareness of prenatal genetic concerns grows. Due to the higher
rates of miscarriage and complications, non-invasive prenatal testing is
expected to become the standard procedure in the future, replacing previous,
riskier screening methods. With a detection accuracy above 99 percent and a
shorter screening time compared to other prenatal screening methods, NIPT
stands out. Limited companies currently offer non-invasive prenatal testing.
The market's growth is driven by the higher risk of chromosomal abnormalities
with increasing maternal age, the rising incidence of chromosomal aneuploidies
among fetuses, the development of advanced non-invasive prenatal testing
products, and improvements in reimbursement. Moreover, the increasing awareness
of non-invasive prenatal testing and untapped market potential in emerging
nations in Asia provide significant revenue growth opportunities for market
participants. The growing preference for non-invasive techniques over invasive
methods is also attracting market expansion.,” said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based management consulting firm.
“Non-invasive
Prenatal Testing (NIPT) Market Global Industry Size, Share, Trends,
Opportunity, and Forecast, 2018-2028 Segmented By Product Type (Consumables,
Instruments), By Test Type (Materni 21, Harmony, Panaroma, Verifi, NIFTY,
Others), By Method (Ultrasound Detection, Biochemical Screening Testing,
Cell-Free DNA Maternal Plasma Tests, Fetal Cells in Maternal Blood Tests,
Others), By Application (Trisomy, Microdeletion Syndrome, Others), By End User
(Diagnostic Laboratories, Hospitals, Others), By Region and Competition”, has evaluated the future growth
potential of Global Non-invasive Prenatal Testing (NIPT) Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Non-invasive Prenatal Testing (NIPT)
Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email:
[email protected]
Website: https://www.techsciresearch.com